MediciNova Announces FDA Clearance for Phase 2 Trial Of MN-001 In IPF

MediciNova Announces FDA Clearance for Phase 2 Trial Of MN-001 In IPF

MedicinovaMediciNova, Inc., a biopharmaceutical company, recently announced that the FDA (U.S. Food and Drug Administration) has approved thecompany’s protocol for a MN-001 (tipelukast) clinical trial to address moderate to severe idiopathic pulmonary fibrosis (IPF). Supported by previous safety data from other clinical studies of MN-001, the FDA granted MediciNova clearance to proceed the first Phase 2 study of MN-001 for IPF, under MediciNova’s open IND (Investigational New Drug Application). Once the FDA grants the drug final approval, the orphan drug designation provides 7 years of commercializing exclusivity to MediciNova.

The CEO and president of MediciNova, Dr. Yuichi Iwaki, commented in a press release: “We are very pleased that this important regulatory step is now completed, as we can now pursue clinical development of MN-001 in IPF.”

MN-001 (tipelukast) is an orally- and bio-available small molecule compound that achieves its therapeutic effects through various mechanisms to achieve both anti-inflammatory and anti-fibrotic activity in pre-clinical models including inhibition of 5-lipoxygenase (5-LO), inhibition of phosphodiesterases (PDE) and leukotriene (LT) receptor antagonism. The MN-001’s inhibitory effect on 5-LO as well the 5-LO/LT pathway is considered a new approach to treat fibrosis. Further, it has been shown that MN-001 can down-regulate the expression of genes that promote inflammation including the MCP-1 and CCR2. Finally histopathological data demonstrated that MN-001 reduces fibrosis in animal models.

MN-001 has been previously assessed by MediciNova for asthma and it obtained good Phase 2 results. The compound has been exposed to more than 600 individuals and safety and tolerance have been satisfactory.

Notes About MediciNova

MediciNova is a biopharmaceutical company focused on advancing new therapeutic approaches through small-molecule therapeutics to address diseases with unmet medical needs. The company’s leading strategies are comprised of MN-166 (ibudilast) to address multiple sclerosis, amyotrophic lateral sclerosis and substance addiction and MN-001 (tipelukast) to address nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis and other fibrotic disease. Finally, MN-221 (bedoradrine) to treat acute exacerbations caused by asthma and MN-029 (denibulin) to treat solid tumor cancers are other projects that MediciNova is developing. More information is available in


How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published.